Literature DB >> 9452400

What makes Cryptococcus neoformans a pathogen?

K L Buchanan1, J W Murphy.   

Abstract

Life-threatening infections caused by the encapsulated fungal pathogen Cryptococcus neoformans have been increasing steadily over the past 10 years because of the onset of AIDS and the expanded use of immunosuppressive drugs. Intricate host-organism interactions make the full understanding of pathogenicity and virulence of C. neoformans difficult. We discuss the current knowledge of the characteristics C. neoformans must possess to enter the host and establish progressive disease: basic growth requirements and virulence factors, such as the polysaccharide capsule; shed products of the organism; melanin production; mannitol secretion; superoxide dismutase; proteases; and phospholipases.

Entities:  

Mesh:

Year:  1998        PMID: 9452400      PMCID: PMC2627665          DOI: 10.3201/eid0401.980109

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  99 in total

1.  Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes.

Authors:  A Vecchiarelli; C Retini; C Monari; C Tascini; F Bistoni; T R Kozel
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Production of the hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis.

Authors:  B Wong; J R Perfect; S Beggs; K A Wright
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

3.  Tolerance to cryptococcal polysaccharide in cured cryptococcosis patients: failure of antibody secretion in vitro.

Authors:  D K Henderson; V L Kan; J E Bennett
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

4.  Cryptococcus neoformans. II. Phagocytosis by human leukocytes.

Authors:  G S Bulmer; M D Sans
Journal:  J Bacteriol       Date:  1967-11       Impact factor: 3.490

5.  Biochemical and molecular characterization of the diphenol oxidase of Cryptococcus neoformans: identification as a laccase.

Authors:  P R Williamson
Journal:  J Bacteriol       Date:  1994-02       Impact factor: 3.490

6.  Proteolytic activity of a clinical isolate of Cryptococcus neoformans.

Authors:  C H Brueske
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

7.  Genetic association of mating types and virulence in Cryptococcus neoformans.

Authors:  K J Kwon-Chung; J C Edman; B L Wickes
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

8.  Melanogenesis in Cryptococcus neoformans.

Authors:  I Polacheck; K J Kwon-Chung
Journal:  J Gen Microbiol       Date:  1988-04

9.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

10.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

View more
  92 in total

1.  Variants of a Cryptococcus neoformans strain elicit different inflammatory responses in mice.

Authors:  L C Chen; A Casadevall
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Does amoeboid reasoning explain the evolution and maintenance of virulence factors in Cryptococcus neoformans?

Authors:  S M Levitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 3.  Strategies for the identification of virulence determinants in human pathogenic fungi.

Authors:  R Alonso-Monge; F Navarro-García; E Román; B Eisman; C Nombela; J Pla
Journal:  Curr Genet       Date:  2003-02-08       Impact factor: 3.886

Review 4.  A yeast under cover: the capsule of Cryptococcus neoformans.

Authors:  Indrani Bose; Amy J Reese; Jeramia J Ory; Guilhem Janbon; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2003-08

5.  Pleiotropic function of intersectin homologue Cin1 in Cryptococcus neoformans.

Authors:  Gui Shen; Amy Whittington; Kejing Song; Ping Wang
Journal:  Mol Microbiol       Date:  2010-03-16       Impact factor: 3.501

6.  Gene disruption in Cryptococcus neoformans and Cryptococcus gattii by in vitro transposition.

Authors:  Guanggan Hu; James W Kronstad
Journal:  Curr Genet       Date:  2006-01-06       Impact factor: 3.886

7.  Systematic survey of nonspecific agglutination by Candida spp. in latex assays.

Authors:  Karsten Becker; Ahmed S Almasri; Christof von Eiff; Georg Peters; Christine Heilmann; Wolfgang Fegeler
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

8.  Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly.

Authors:  Pardeep Kumar; Christian Heiss; Felipe H Santiago-Tirado; Ian Black; Parastoo Azadi; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2014-02-28

9.  Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier.

Authors:  Yun C Chang; Monique F Stins; Michael J McCaffery; Georgina F Miller; Dan R Pare; Tapen Dam; Maneesh Paul-Satyaseela; Kwang Sik Kim; Kyung J Kwon-Chung; Maneesh Paul-Satyasee
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

10.  Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan.

Authors:  Javier García-Rivera; Yun C Chang; K J Kwon-Chung; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2004-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.